Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier LabfiledCriticalServier Lab
Priority to CU20040294ApriorityCriticalpatent/CU23397B7/en
Publication of CU23397B7publicationCriticalpatent/CU23397B7/en
La presente invención se relaciona con cápsulas que permiten la liberación retardada y controlada del perindropil, o de una de sus sales farmacéuticamente aceptables, destinadas a una administración por vía oral.The present invention relates to capsules that allow the delayed and controlled release of perindropyl, or of a pharmaceutically acceptable salt thereof, intended for oral administration.
CU20040294A2004-12-242004-12-24
RESERVE MICROCAPPS FOR SLOW AND CONTROLLED RELEASE OF PERINDOPRIL.
CU23397B7
(en)
Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
Compounds derived from (methylsulfonyl) -ethyl-benzenoisoindoline; pharmaceutical composition that comprises them, use in the treatment of cancer, pain, CNS disorders, dermatological diseases, among others.
PHARMACEUTICAL COMPOSITIONS TO TREAT SKIN DISEASES THAT INCLUDE A COMBINATION OF EPINASTINE AND ONE OR MORE ADDITIONAL MINERALS OR ONE OR MORE GROSS PHARMACOS
USE OF MEQUITAZINE IN THE FORM OF A RACEMATE OR ENANTIOMER FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES THAT INVOLVE H4 HISTAMINAL RECEIVERS